Breast Cancer

According to results presented at the 2017 AACR Annual Meeting, 10% of patients showed impressive long-term survival in a phase I study of single agent anti-PD-L1 atezolizumab (Tecentriq) in patients with metastatic triple-negative breast cancer.

The irreversible pan-HER tyrosine kinase inhibitor neratinib showed single-agent activity across cohorts of patients with HER2-mutant advanced cancers.

The FDA has granted a full approval to palbociclib (Ibrance) for use in combination with letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer.

Sara A. Hurvitz, MD, discussed the use of anthracycline regimens in breast cancer during a talk at the 2017 Miami Breast Cancer Conference.

Mark D. Pegram, MD, discusses resistance mechanisms being studied in the quest to overcome resistance to HER2-targeted therapy in breast cancer.

Adam M. Brufsky, MD, PhD, discusses considerations for using denosumab and zoledronic acid in patients with breast cancer.

Mohammad Jahanzeb, MD, discusses the SystHERs trial, which was designed to provide real-world insight into current treatment patterns, long-term survival, and patient experience with multiple different treatments for HER2-positive metastatic breast cancer.

Leslie Schover, PhD, discusses strategies to help patients with breast cancer who have sexuality and fertility issues.

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the benefits of dual-targeted therapy for patients with HER2-positive breast cancer.

Male breast cancer is a rare and poorly understood disease, but recent molecular studies have revealed fundamental differences from female breast cancer that could help guide treatment strategies toward a more tailored approach.

Whereas the androgen receptor (AR) is a common target in prostate cancer, emerging findings are showing a potential role for targeting AR in breast cancer, as well.

Immune checkpoint inhibitors in triple-negative breast cancer are showing promise, but there must be future research to determine whether these agents can make a difference in this challenging malignancy.

Sara Hurvitz, MD, discusses the amazing evolution in the available treatment options for patients with HER2-positive breast cancer.

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the future of adjuvant treatment in HER2-positive breast cancer.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses standard and emerging advances in the treatment of patients with HER2-positive breast cancer.

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment for patients with triple-negative breast cancer (TNBC).

In the phase III MONARCH 2 study, adding abemaciclib to fulvestrant improved progression-free survival compared with fulvestrant alone in women with hormone receptor-positive/HER2-negative breast cancer.

Wolfgang Janni, MD, PhD, University of Ulm, disucusses the management of adverse events in HER2-targeted therapies.

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.

Neoadjuvant therapy in early breast cancer has evolved during the past 2 decades from use primarily in large inoperable tumors to a standard treatment option for patients with early-stage HER2-positive and triple-negative breast cancer.

Age and the molecular subtype were more closely associated with long-term outcomes compared with the use of either breast-conserving surgery or mastectomy for patients with breast cancer.

Immunotherapy will be most effective as a treatment for breast cancer when it is used to alter the tumor microenvironment, according to a careful examination of studies exploring the immune response presented by Nora Disis, MD.

Inhibition of CDK4/6 results in improvements in progression-free survival in women with estrogen receptor-positive/HER2-negative metastatic breast cancer whether it is endocrine sensitive or resistant.

Giuseppe Curigliano, MD, PhD, discusses recent trials of immunotherapy and chemotherapy in triple-negative breast cancer, as well as the future role of immunotherapy in the treatment of breast cancer.

Daniel F. Hayes, MD, professor University of Michigan Comprehensive Cancer Center, discusses the use of tumor biomarker tests in breast cancer.